PDCD1 and glioblastoma: While neither anti-TIM-3 nor SRS alone prolonged survival of GBM-bearing mice, combining the two increased median survival from 22 to 100 days, an effect similarly obtained using an anti-TIM-3 and anti-PD-1 combination [66].